文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

肥厚型心肌病中睡眠呼吸障碍的患病率与临床意义

Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy.
PubMed 文献 · JAMA Cardiol · 2025-01-01

这项前瞻性队列研究在单中心纳入154例成人肥厚型心肌病患者,通过多导睡眠图诊断睡眠呼吸障碍(SDB)。59.1%的患者存在未诊断的SDB,且SDB与更高的左室质量指数、E/e'比值、基线及夜间肌钙蛋白T水平以及更差的NYHA心功能分级相关。

要点

  • 肥厚型心肌病患者中未诊断的睡眠呼吸障碍患病率高达59.1%。
  • SDB与左室质量指数、E/e'比值升高及肌钙蛋白T水平升高相关。
  • SDB患者NYHA II/III级症状更常见,提示症状负担加重。

核心结论

  • 肥厚型心肌病患者中未诊断的睡眠呼吸障碍高发,且与不良心肌重构、舒张功能减退和亚临床心肌损伤相关。

研究设计与样本

  • 前瞻性队列研究,2018年4月18日至2024年1月15日在单中心三级转诊中心进行,纳入154例成人肥厚型心肌病患者(左室壁厚度≥15 mm或致病性变异),排除已诊断SDB或妊娠者,所有患者接受多导睡眠图检查。

主要发现

  • 154例患者中91例(59.1%)诊断为SDB。

临床怎么用

  • 对肥厚型心肌病患者应考虑筛查睡眠呼吸障碍,尤其存在舒张功能障碍、肌钙蛋白升高或症状负担重者。
  • SDB可能与HCM病理生理相关,支持开展随机临床试验评估治疗SDB对症状和临床结局的影响。

局限性

  • 单中心研究,样本量有限,结果外推需谨慎。
  • 为观察性研究,无法确定SDB与HCM不良表型之间的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sleep disordered breathing (SDB) is a well-established contributor to cardiovascular morbidity, mediated by intermittent hypoxemia, autonomic dysregulation, and endothelial dysfunction. Patients with hypertrophic cardiomyopathy (HCM) may be especially at risk for SDB, but the clinical impact of SDB in this population remains unclear. OBJECTIVE: To define the prevalence and subtypes of SDB in HCM and examine their association with echocardiographic parameters and cardiac biomarker expression. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study was conducted between April 18, 2018, and January 15, 2024, at a single tertiary referral center specializing in HCM care. Adults with HCM (left ventricular wall thickness ≥15 mm or pathogenic variants) were recruited from an institutional registry. Patients diagnosed with SDB or current pregnancy were excluded. Patients underwent polysomnography, with comparative assessment of echocardiographic, electrocardiographic, and biomarker indices. Observers were blinded to polysomnographic results. Data analysis was performed from April 11, 2024, to July 25, 2024. EXPOSURES: SDB classified via polysomnography using apnea-hypopnea index thresholds, with subtypes including obstructive sleep apnea and central sleep apnea and with event severity, hypoxemia, and sleep architecture disruption quantified. MAIN OUTCOMES AND MEASURES: Echocardiographic indices, cardiac biomarker expression, functional status, apnea-hypopnea index, and overnight hypoxemia. RESULTS: Among 154 patients (median [IQR] age, 60 [48-68] years; 102 [66.2%] male), 91 (59.1%) were diagnosed with SDB. Those with SDB, compared with those without SDB, had higher left ventricular mass index (median [IQR], 128 [107-161] vs 109 [96-134] g/m2; P = .03), E/e' ratio (median [IQR], 12.5 [10.0-15.0] vs 10.0 [8.3-14.5]; P = .04), and baseline troponin-T level (median [IQR], 0.013 [0.009-0.022] vs 0.011 [0.007-0.015] ng/mL [to convert to micrograms per liter, multiply by 1]; P = .04) and greater overnight troponin-T level increases (change in median [IQR], 0.0021 [-0.0029 to 0.0062] vs 0.0002 [-0.0022 to 0.0026] ng/mL; P = .02). New York Heart Association class II or III symptoms were more common in those with SDB (48 [52.7%] vs 17 [27.0%]; P = .005). Hypertension and diabetes were more prevalent among patients with SDB than without SDB (hypertension: 67 [73.6%] vs 36 [57.1%]; P = .03; diabetes: 14 [15.4%] vs 3 [4.8%]; P = .04), whereas rates of atrial fibrillation and prior myectomy did not differ significantly between groups. CONCLUSIONS AND RELEVANCE: This study suggests that undiagnosed SDB is highly prevalent in patients with HCM and that SDB is associated with adverse myocardial remodeling, greater diastolic dysfunction, and elevated troponin-T levels, indicating subclinical myocardial injury. SDB may contribute to HCM pathophysiology and symptom burden, supporting the rationale for randomized clinical trials to determine the impact of treating SDB on symptoms and clinical outcomes in patients with HCM.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Karim S, Chahal A, Venkataraman S, et al. Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy. JAMA Cardiol. 2025. PMID: 40900558. doi:10.1001/jamacardio.2025.2877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。